Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
ConclusionsSubcutaneous tanezumab, compared with placebo, reduced pain within the first week, and pain and function were improved throughout 24 weeks. The proportions of responders and patients satisfied were higher with tanezumab than placebo.
Source: European Journal of Pain - Category: Anesthesiology Authors: F. Berenbaum,
R. Langford,
S. Perrot,
K. Miki,
F.J. Blanco,
T. Yamabe,
N. Isogawa,
R. Junor,
W. Carey,
L. Viktrup,
C.R. West,
M.T. Brown,
K.M. Verburg Tags: ORIGINAL ARTICLE Source Type: research
MedWorm Privacy Policy
Disclaimer
Copyright © MedWorm 2006-2024